Tianjin Ringpu Bio Tech (300119) - Total Liabilities
Based on the latest financial reports, Tianjin Ringpu Bio Tech (300119) has total liabilities worth CN¥2.54 Billion CNY (≈ $371.81 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Tianjin Ringpu Bio Tech operating cash flow efficiency to assess how effectively this company generates cash.
Tianjin Ringpu Bio Tech - Total Liabilities Trend (2007–2024)
This chart illustrates how Tianjin Ringpu Bio Tech's total liabilities have evolved over time, based on quarterly financial data. Check Tianjin Ringpu Bio Tech liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Tianjin Ringpu Bio Tech Competitors by Total Liabilities
The table below lists competitors of Tianjin Ringpu Bio Tech ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Strait Innovation Internet Co Ltd
SHE:300300
|
China | CN¥833.90 Million |
|
Rush Enterprises B Inc
NASDAQ:RUSHB
|
USA | $2.20 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥24.43 Billion |
|
Tibet GaoZheng Explosive Co Ltd
SHE:002827
|
China | CN¥-1.28 Billion |
|
Power HF Co Ltd
SHG:605100
|
China | CN¥455.28 Million |
|
IRSA Inversiones y Representaciones SA
BA:IRSA
|
Argentina | AR$2.22 Trillion |
|
Monte Rosa Therapeutics Inc
NASDAQ:GLUE
|
USA | $214.00 Million |
|
Hna-Caissa Travel Group Co Ltd
SHE:000796
|
China | CN¥967.96 Million |
Liability Composition Analysis (2007–2024)
This chart breaks down Tianjin Ringpu Bio Tech's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Tianjin Ringpu Bio Tech market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.08 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.54 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.33 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Tianjin Ringpu Bio Tech's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Tianjin Ringpu Bio Tech (2007–2024)
The table below shows the annual total liabilities of Tianjin Ringpu Bio Tech from 2007 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥2.96 Billion ≈ $432.97 Million |
+65.20% |
| 2023-12-31 | CN¥1.79 Billion ≈ $262.09 Million |
+11.58% |
| 2022-12-31 | CN¥1.61 Billion ≈ $234.89 Million |
+17.41% |
| 2021-12-31 | CN¥1.37 Billion ≈ $200.05 Million |
+17.63% |
| 2020-12-31 | CN¥1.16 Billion ≈ $170.07 Million |
-3.64% |
| 2019-12-31 | CN¥1.21 Billion ≈ $176.50 Million |
+62.11% |
| 2018-12-31 | CN¥744.03 Million ≈ $108.88 Million |
-0.52% |
| 2017-12-31 | CN¥747.95 Million ≈ $109.45 Million |
+19.15% |
| 2016-12-31 | CN¥627.74 Million ≈ $91.86 Million |
+8.28% |
| 2015-12-31 | CN¥579.77 Million ≈ $84.84 Million |
+125.39% |
| 2014-12-31 | CN¥257.23 Million ≈ $37.64 Million |
-9.07% |
| 2013-12-31 | CN¥282.89 Million ≈ $41.40 Million |
+36.67% |
| 2012-12-31 | CN¥206.99 Million ≈ $30.29 Million |
+18.20% |
| 2011-12-31 | CN¥175.12 Million ≈ $25.63 Million |
-10.50% |
| 2010-12-31 | CN¥195.66 Million ≈ $28.63 Million |
+20.31% |
| 2009-12-31 | CN¥162.63 Million ≈ $23.80 Million |
+90.93% |
| 2008-12-31 | CN¥85.18 Million ≈ $12.46 Million |
+69.48% |
| 2007-12-31 | CN¥50.26 Million ≈ $7.35 Million |
-- |
About Tianjin Ringpu Bio Tech
Tianjin Ringpu Bio-Technology Co.,Ltd. engages in the research and development, production, and sale of veterinary raw materials, drug preparation, functional additives, and veterinary biological products. The company provides anthelmintics, pet vaccines, ear canal treatment drugs, anesthetic analgesics, antibiotics, antivirals, various internal medicine drugs, as well as disinfectant products, i… Read more